Current Report Filing (8-k)
February 16 2023 - 09:16AM
Edgar (US Regulatory)
0001680378
false
0001680378
2023-02-15
2023-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 15, 2023
SenesTech,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-37941 |
|
20-2079805 |
(State or other jurisdiction
of incorporation) |
|
(Commission File No.) |
|
(IRS Employer
Identification No.) |
23460
N. 19th Avenue,
Suite 110
Phoenix,
AZ 85027
(Address
of principal executive offices) (Zip Code)
(928)
779-4143
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, $0.001 par
value |
|
SNES |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ CFR 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ CFR 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
February 16, 2023, we issued a press release containing material non-public information regarding our fourth quarter and year ended December
31, 2022. A copy of our press release is attached as Exhibit 99.1 to this Current Report on Form 8- K and incorporated herein by reference.
The
information in this Item 2.02 (including Exhibit 99.1) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,
or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific
reference in such a filing.
We
do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any changes
in events, conditions, or circumstances on which any forward-looking statement is based.
The
text included with this Current Report on Form 8-K is available on our website at www.senestech.com, although we reserve the right
to discontinue that availability at any time.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
February 15, 2023, we appointed Nicole Williams as Chief Revenue Officer. Ms. Williams was previously serving as our Chief Strategy Officer.
Ms.
Williams, age 43, previously served as Chief Strategy Officer of our company from May 2021 to February 2023 and assumed leadership of
our commercialization activities as of the end of 2021. Prior to joining our company, she was the National Director of Sales and Business
Development in the orthopedic robotics division of Smith+Nephew, driving the adoption and commercialization of new technology with healthcare
facilities across the country, from July 2018 to May 2021. From July 2017 to July 2018, Mrs. Williams served as Facility Administrator
at DaVita Kidney Care. Previously, from September 2011 to July 2017, she was Assistant Vice President of Marketing and Public Relations
for an HCA Level 1 Trauma Center driving service line growth, expansion of beds and services, and overall facility operations. Nicole’s
20-years of experience include sales and business development, operations, marketing, and crisis communications. Nicole earned a bachelor’s
degree at Boston University and an M.B.A. from the University of Denver.
Ms.
Williams has no family relationship with any of the executive officers or directors of our company. There are no arrangements or understandings
between Ms. Williams and any other person pursuant to which she was elected as an officer of our company.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
February 16, 2023
|
SENESTECH, INC. |
|
|
|
|
By: |
/s/ Thomas
C. Chesterman |
|
|
Thomas C. Chesterman |
|
|
Executive Vice President, Chief Financial Officer,
Treasurer, and Secretary |
2
SenesTech (NASDAQ:SNES)
Historical Stock Chart
From Feb 2024 to Mar 2024
SenesTech (NASDAQ:SNES)
Historical Stock Chart
From Mar 2023 to Mar 2024